Cognoa, Inc.

Cognoa is a pediatric behavioral health company developing AI-powered digital diagnostics and therapeutics for early childhood developmental conditions, with a focus on autism spectrum disorder. The company's flagship product, Canvas Dx™, is the first FDA-authorized digital diagnostic aid for autism in children aged 1.5 to 6 years, enabling remote evaluation and rapid diagnosis within days rather than months or years. Canvas Dx combines analysis of parent questionnaires and child behavior video to provide objective, data-driven diagnostic support that reduces diagnostic delays, healthcare costs, and disparities in care access—particularly for underserved and minority populations. The platform has achieved reimbursement coverage through Highmark Insurance and multiple state Medicaid programs. Beyond autism diagnostics, Cognoa is expanding its AI platform to address other pediatric behavioral health conditions including ADHD and anxiety, with a commitment to equitable, early intervention in developmental health assessment and treatment.